Vir Biotechnology shares surge on successful Phase 3 clinical trial for hepatitis B treatment
VIR Vir Biotechnology Inc
$13.65 +11.75%
View chart & analysis → - 1Vir Biotechnology met its primary endpoint in the 124-patient Phase 3 Eclipse-1 clinical trial.
- 2After 48 weeks, 79% of patients treated in the Eclipse-1 trial reached undetectable virus levels.
- 3VIR shares surged 11% on Friday, achieving a year-to-date return of approximately 102%.
So what's the key point?
Vir Biotechnology's hepatitis treatment trial was effective, with 79% of patients reaching undetectable virus levels. Following this news, the stock price rose 11%, resulting in a strong year-to-date return.
Source Stocktwits +6 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.